Cytovance Biologics
Oklahoma City, OK
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
78.6
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
✓ Press (8)
○ EMA GMP
○ MHRA GMP
Quick Facts: Cytovance Biologics
- Signal Score
- 78.6/100 (as of 2026-09-07)
- Quality Compliance
- 98.1/100
- Headquarters
- Oklahoma City, OK
- Founded
- 2006
- Max Bioreactor Scale
- 2,000L
- Website
- https://cytovance.com/
- Modalities
- Microbial Fermentation, Biologics, Recombinant Proteins, Mammalian Cell Culture, Plasmid DNA
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
98.1
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2026-06-17)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMicrobial Fermentation, Biologics, Recombinant Proteins, Mammalian Cell Culture, Plasmid DNA
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
63.0
Capacity status: Available
StatusAvailable
Recent Press8 articles
Cytovance Biologics FDA Inspection History
2026-06
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2026-06-17 |
Cytovance Biologics Inc.
Oklahoma City, Oklahoma
Facility-linked
|
Drug Quality Assurance | No | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Oct 07, 2026
Recent News 8 articles
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - BioSpace
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing BioSpace
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Sahm
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing Sahm
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing - irw-press.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing irw-press.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - StreetInsider
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing StreetInsider
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Yahoo Finance Singapore
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing Yahoo Finance Singapore
Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Trials with Cytovance Biologics as cGMP Manufacturer - geneonline.com
Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Trials with Cytovance Biologics as cGMP Manufacturer geneonline.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - PR Newswire
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing PR Newswire
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Morningstar
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing Morningstar
Frequently Asked Questions About Cytovance Biologics
How many FDA inspections does Cytovance Biologics have on record?
CDMO Signal tracks 1 FDA inspection for Cytovance Biologics, sourced from the FDA inspection database. See the full inspection history above.
Has Cytovance Biologics received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Cytovance Biologics.
What is Cytovance Biologics's CDMO Signal Score?
Cytovance Biologics has a Signal Score of 79/100, based on quality, operations, financial stability, and capacity data.
Evaluating Cytovance Biologics for a manufacturing program?
Use the free AI matchmaker to compare Cytovance Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Richter BioLogics
Hamburg, Germany
Signal Score: 82.9
Plasmid DNA, Recombinant Proteins, VHH/Nanobodies, Bacterial Vaccines, Biologics
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 91.5
Biologics, mRNA
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 84.8
AAV, mRNA/LNP, Biologics, mRNA
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 84.4
Monoclonal Antibody, Recombinant Protein, AAV (analytical only), Plasmid DNA
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 83.5
Oligonucleotide, Biologics, AAV